<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876887</url>
  </required_header>
  <id_info>
    <org_study_id>STU00202741</org_study_id>
    <secondary_id>R21AG050897</secondary_id>
    <nct_id>NCT02876887</nct_id>
  </id_info>
  <brief_title>Cocoa to Improve Walking Performance in Peripheral Artery Disease</brief_title>
  <acronym>COCOA-PAD</acronym>
  <official_title>Cocoa to Improve Walking Performance in Peripheral Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COCOA-PAD trial will determine whether epicatechin-rich cocoa daily for six months&#xD;
      improves walking performance in individuals with peripheral artery disease compared to&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapeutic properties that target pathophysiologic impairments in PAD. These therapeutic&#xD;
      properties include improved skeletal muscle mitochondrial function, increased skeletal muscle&#xD;
      capillary density, and favorable changes in skeletal muscle levels of myostatin and&#xD;
      follistatin that increase muscle mass and strength. Cocoa also protects against&#xD;
      ischemia-reperfusion injury, improves endothelial function, and reduces oxidative stress. In&#xD;
      summary, epicatechin-rich cocoa targets and reverses several pathophysiologic processes that&#xD;
      are common in PAD and that are associated with functional impairment and functional decline&#xD;
      in PAD. However, the effect of chronic daily cocoa consumption on functional decline has not&#xD;
      been studied in older people with PAD.&#xD;
&#xD;
      The COCOA-PAD trial is a pilot study of 44 PAD participants age 60 and older: a double-blind,&#xD;
      randomized controlled pilot clinical trial to provide preliminary data to address the&#xD;
      hypothesis that chronic daily epicatechin-rich cocoa improves lower extremity functioning in&#xD;
      older people with PAD by improving mitochondrial oxidative metabolism, increasing calf muscle&#xD;
      capillary density, promoting calf skeletal muscle mitochondrial biogenesis, and improving&#xD;
      endothelial function.&#xD;
&#xD;
      In the primary aim, the investigators will determine whether PAD participants randomized to&#xD;
      an epicatechin-rich cocoa beverage have greater increases or smaller declines in six-minute&#xD;
      walk performance at 6-month follow-up, compared to those randomized to an identical appearing&#xD;
      placebo drink with comparable caloric composition. In the secondary aims, the investigators&#xD;
      will determine whether PAD participants randomized to cocoa have improved treadmill walking&#xD;
      performance, improved brachial artery flow-mediated dilation, favorable changes in calf&#xD;
      muscle biopsy measures of mitochondrial function, mitochondrial biogenesis, follistatin,&#xD;
      myostatin, and capillary density, increased calf skeletal muscle regeneration and reduced&#xD;
      oxidative stress, and increased MRI-measured calf muscle perfusion. Outcome measures will be&#xD;
      carefully timed relative to the last intervention dose to distinguish between the acute vs.&#xD;
      chronic effects of cocoa-epicatechin.&#xD;
&#xD;
      If the hypotheses are correct, results will be used to design a large, definitive randomized&#xD;
      controlled trial of epicatechin-rich cocoa to improve lower extremity functioning and prevent&#xD;
      mobility loss in the large and growing number of older people who are disabled by PAD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">October 15, 2019</completion_date>
  <primary_completion_date type="Actual">October 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Six-minute Walk Distance</measure>
    <time_frame>Change from baseline to six-month follow-up. Note - There will be two measures: One 2-3 hours after the final study beverage dose and one 24 hours after the final dose.</time_frame>
    <description>Following a standardized protocol, participants walked up and down a 100-ft hallway for 6 minutes after instruction to cover as much distance as possible.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Maximal and Pain-free Treadmill Walking Time</measure>
    <time_frame>Change from baseline to six-month follow-up</time_frame>
    <description>Maximal treadmill walking time and time to ischemic leg symptom onset were measured using the Gardner-Skinner protocol at baseline and 6-month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline From Brachial Artery Flow-mediated Dilation: Change in Brachial Artery Diameter</measure>
    <time_frame>Change from baseline to six-month follow-up. Note - there will be two measures: One 2-3 hours after the final study beverage dose and one 24 hours after the final study beverage dose.</time_frame>
    <description>Brachial artery flow-mediated dilation was measured in the proximal brachial artery (B mode and Doppler) after a 12-hour fast by Registered Diagnostic Cardiac Sonographers using a linear array vascular ultrasound transducer (Sequoia Model #256; frequency, 8 MHz; range, 5-8 MHz; Siemens Medical Solutions). A cuff proximal to the visualized brachial artery segment was inflated for 4 minutes at 50 mmHg above systolic pressure. Brachial artery images were obtained 60 seconds after cuff deflation and interpreted by a single reader, blinded to group assignment, at the University of Wisconsin Atherosclerosis Imaging Research Program Core Laboratory. Change in brachial artery diameter will be reported in percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Accelerometer-measured Physical Activity</measure>
    <time_frame>Change from baseline to six-month follow-up</time_frame>
    <description>Free-living physical activity was acquired over 7 days with the ActiGraph accelerometer. The accelerometer was worn on the right hip and removed only for bathing or sleeping.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline Calf Skeletal Muscle Measures: Abundance of PGC1α, Myostatin and Follistatin</measure>
    <time_frame>Change from baseline to six-month follow-up</time_frame>
    <description>An open-muscle biopsy at baseline was performed in the medial head of the gastrocnemius muscle. Anesthesia was achieved with subcutaneous lidocaine. Subcutaneous tissue was dissected, and ≈250 mg of muscle was removed and immediately prepared for freezing at -80°C. At 6-month follow-up, the biopsy was repeated, adjacent to the original biopsy, identifiable by the scar.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline MRI-Measured Calf Skeletal Muscle Perfusion</measure>
    <time_frame>Change from baseline to six-month follow-up</time_frame>
    <description>Arterial spin labeling with cardiovascular magnetic resonance imaging was used to measure changes in calf perfusion at 3 T between PAD participants receiving cocoa versus placebo. A thigh cuff was inflated to 250 mm Hg in the leg with the lowest ABI and rapidly deflated after 5 minutes. Seven control-tagged image pairs were acquired over 60 seconds using pulsed arterial spin labeling pulse sequence with single-shot echo-planar imaging readouts ( eld of view, 200×200 mm; matrix, 64×64; repetition time, 4000 ms; echo time, 32 ms; slice thickness, 10 mm). Perfusion was measured and quantified on a Siemens Healthcare workstation by coinvestigator C.M.K.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline Calf Skeletal Muscle Measures: Citrate Synthase and COX Activity</measure>
    <time_frame>Change from baseline to six-month follow-up</time_frame>
    <description>An open-muscle biopsy at baseline was performed in the medial head of the gastrocnemius muscle. Anesthesia was achieved with subcutaneous lidocaine. Subcutaneous tissue was dissected, and ≈250 mg of muscle was removed and immediately prepared for freezing at -80°C. At 6-month follow-up, the biopsy was repeated, adjacent to the original biopsy, identifiable by the scar.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cocoa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three servings per day of placebo beverages for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocoa</intervention_name>
    <arm_group_label>Cocoa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All participants will be age 60 and older.&#xD;
&#xD;
          2. All participants will have PAD. PAD will be defined as follows. First, an ABI &lt; 0.90&#xD;
             at baseline is an inclusion criterion for PAD. Second, potential participants with an&#xD;
             ABI &gt; 0.90 who have vascular lab evidence of PAD or angiographic evidence of PAD will&#xD;
             be eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Above- or below-knee amputation.&#xD;
&#xD;
          2. Critical limb ischemia.&#xD;
&#xD;
          3. Wheelchair-bound or requiring a cane or walker to ambulate.&#xD;
&#xD;
          4. Walking is limited by a symptom other than PAD.&#xD;
&#xD;
          5. Baseline six-minute walk value of &lt;500 feet or &gt;1,600 feet&#xD;
&#xD;
          6. Lower extremity revascularization, major orthopedic surgery, cardiovascular event, or&#xD;
             coronary revascularization in the previous three months.&#xD;
&#xD;
          7. Planned revascularization or major surgery during the next six months.&#xD;
&#xD;
          8. Major medical illness including renal disease requiring dialysis, lung disease&#xD;
             requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy&#xD;
             less than six months, or cancer requiring treatment in the previous two years. [NOTE:&#xD;
             potential participants may still qualify if they have had treatment for an early stage&#xD;
             cancer in the past two years and the prognosis is excellent. Participants who require&#xD;
             oxygen only at night may still qualify.]&#xD;
&#xD;
          9. Mini-Mental Status Examination (MMSE) score &lt; 23 or dementia.&#xD;
&#xD;
         10. Unwilling to attend three visits in one week for final outcome measures.&#xD;
&#xD;
         11. Allergy to chocolate.&#xD;
&#xD;
         12. Unwilling or unable to consume products manufactured on the same equipment that&#xD;
             processes peanuts, tree nuts, egg, wheat, soy, and milk.&#xD;
&#xD;
         13. Use of cocoa-containing dietary supplements.&#xD;
&#xD;
         14. Unwilling to give up major dietary sources of epicatechin during the study.&#xD;
&#xD;
         15. Symptoms of heart failure or angina that limit walking activity more than ischemic leg&#xD;
             symptoms, increase in angina, or angia at rest (i.e. unstable angina).&#xD;
&#xD;
         16. Participation in or completion of a clinical trial in the previous three months.&#xD;
             [NOTE: after completing a stem cell or gene therapy intervention, participants will&#xD;
             become eligible after the final study follow-up visit of the stem cell or gene therapy&#xD;
             study so long as at least six months have passed since the final intervention&#xD;
             administration. After completing a supplement or drug therapy (other than stem cell or&#xD;
             gene therapy), participants will be eligible after the final study follow-up visit as&#xD;
             long as at least three months have passed since the final intervention of the trial.]&#xD;
&#xD;
         17. Non-English speaking, a visual impairment that limits walking ability.&#xD;
&#xD;
         18. In addition to the above criteria, investigator discretion will be used to determine&#xD;
             if the trial is unsafe or not a good fit for the potential participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary McDermott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <results_first_submitted>May 4, 2020</results_first_submitted>
  <results_first_submitted_qc>July 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2020</results_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Mary McDermott</investigator_full_name>
    <investigator_title>Professor of Medicine at Northwestern University Feinberg School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02876887/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cocoa</title>
          <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cocoa</title>
          <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="7"/>
                    <measurement group_id="B2" value="73" spread="7"/>
                    <measurement group_id="B3" value="72" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Six-minute Walk Distance</title>
        <description>Following a standardized protocol, participants walked up and down a 100-ft hallway for 6 minutes after instruction to cover as much distance as possible.</description>
        <time_frame>Change from baseline to six-month follow-up. Note - There will be two measures: One 2-3 hours after the final study beverage dose and one 24 hours after the final dose.</time_frame>
        <population>Nineteen and 21 study participants in the cocoa and placebo groups, respectively, completed the six-minute walk at both baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Cocoa</title>
            <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Six-minute Walk Distance</title>
          <description>Following a standardized protocol, participants walked up and down a 100-ft hallway for 6 minutes after instruction to cover as much distance as possible.</description>
          <population>Nineteen and 21 study participants in the cocoa and placebo groups, respectively, completed the six-minute walk at both baseline and 6-month follow-up.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Six-month, 2.5 hours after study beverage (meters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="0.34" upper_limit="36.5"/>
                    <measurement group_id="O2" value="-24.2" lower_limit="-40.7" upper_limit="-7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Six-month, 24 hours after study beverage (meters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="-1.9" upper_limit="32.1"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-19.4" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Maximal and Pain-free Treadmill Walking Time</title>
        <description>Maximal treadmill walking time and time to ischemic leg symptom onset were measured using the Gardner-Skinner protocol at baseline and 6-month follow-up.</description>
        <time_frame>Change from baseline to six-month follow-up</time_frame>
        <population>Eighteen and 19 study participants in the cocoa and placebo groups, respectively, participated in both the baseline and 6-month follow-up treadmill test.</population>
        <group_list>
          <group group_id="O1">
            <title>Cocoa</title>
            <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximal and Pain-free Treadmill Walking Time</title>
          <description>Maximal treadmill walking time and time to ischemic leg symptom onset were measured using the Gardner-Skinner protocol at baseline and 6-month follow-up.</description>
          <population>Eighteen and 19 study participants in the cocoa and placebo groups, respectively, participated in both the baseline and 6-month follow-up treadmill test.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximal treadmill minutes, 48 hrs post beverage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-1.16" upper_limit="1.10"/>
                    <measurement group_id="O2" value="0.28" lower_limit="-0.79" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain-free treadmill minutes, 48 hrs post beverage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-1.13" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.39" lower_limit="-0.64" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline From Brachial Artery Flow-mediated Dilation: Change in Brachial Artery Diameter</title>
        <description>Brachial artery flow-mediated dilation was measured in the proximal brachial artery (B mode and Doppler) after a 12-hour fast by Registered Diagnostic Cardiac Sonographers using a linear array vascular ultrasound transducer (Sequoia Model #256; frequency, 8 MHz; range, 5-8 MHz; Siemens Medical Solutions). A cuff proximal to the visualized brachial artery segment was inflated for 4 minutes at 50 mmHg above systolic pressure. Brachial artery images were obtained 60 seconds after cuff deflation and interpreted by a single reader, blinded to group assignment, at the University of Wisconsin Atherosclerosis Imaging Research Program Core Laboratory. Change in brachial artery diameter will be reported in percent change.</description>
        <time_frame>Change from baseline to six-month follow-up. Note - there will be two measures: One 2-3 hours after the final study beverage dose and one 24 hours after the final study beverage dose.</time_frame>
        <population>Fifteen and 17 study participants in the cocoa and placebo groups, respectively, participated in brachial artery flow-mediated dilation at baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Cocoa</title>
            <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline From Brachial Artery Flow-mediated Dilation: Change in Brachial Artery Diameter</title>
          <description>Brachial artery flow-mediated dilation was measured in the proximal brachial artery (B mode and Doppler) after a 12-hour fast by Registered Diagnostic Cardiac Sonographers using a linear array vascular ultrasound transducer (Sequoia Model #256; frequency, 8 MHz; range, 5-8 MHz; Siemens Medical Solutions). A cuff proximal to the visualized brachial artery segment was inflated for 4 minutes at 50 mmHg above systolic pressure. Brachial artery images were obtained 60 seconds after cuff deflation and interpreted by a single reader, blinded to group assignment, at the University of Wisconsin Atherosclerosis Imaging Research Program Core Laboratory. Change in brachial artery diameter will be reported in percent change.</description>
          <population>Fifteen and 17 study participants in the cocoa and placebo groups, respectively, participated in brachial artery flow-mediated dilation at baseline and 6-month follow-up.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FMD change, 2.5 hours after study beverage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-2.08" upper_limit="0.78"/>
                    <measurement group_id="O2" value="0.63" lower_limit="-0.69" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FMD change, 24 hours after study beverage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-1.23" upper_limit="1.32"/>
                    <measurement group_id="O2" value="-0.59" lower_limit="-1.96" upper_limit="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Accelerometer-measured Physical Activity</title>
        <description>Free-living physical activity was acquired over 7 days with the ActiGraph accelerometer. The accelerometer was worn on the right hip and removed only for bathing or sleeping.</description>
        <time_frame>Change from baseline to six-month follow-up</time_frame>
        <population>Fifteen and 19 study participants in the cocoa and placebo groups, respectively, wore an ActiGraph accelerometer at baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Cocoa</title>
            <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Accelerometer-measured Physical Activity</title>
          <description>Free-living physical activity was acquired over 7 days with the ActiGraph accelerometer. The accelerometer was worn on the right hip and removed only for bathing or sleeping.</description>
          <population>Fifteen and 19 study participants in the cocoa and placebo groups, respectively, wore an ActiGraph accelerometer at baseline and 6-month follow-up.</population>
          <units>activity counts</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1919" lower_limit="-17743" upper_limit="13904"/>
                    <measurement group_id="O2" value="-8981" lower_limit="-22743" upper_limit="4780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline Calf Skeletal Muscle Measures: Abundance of PGC1α, Myostatin and Follistatin</title>
        <description>An open-muscle biopsy at baseline was performed in the medial head of the gastrocnemius muscle. Anesthesia was achieved with subcutaneous lidocaine. Subcutaneous tissue was dissected, and ≈250 mg of muscle was removed and immediately prepared for freezing at -80°C. At 6-month follow-up, the biopsy was repeated, adjacent to the original biopsy, identifiable by the scar.</description>
        <time_frame>Change from baseline to six-month follow-up</time_frame>
        <population>Ten and 6 study participants in the cocoa and placebo groups, respectively, completed muscle biopsy at baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Cocoa</title>
            <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Calf Skeletal Muscle Measures: Abundance of PGC1α, Myostatin and Follistatin</title>
          <description>An open-muscle biopsy at baseline was performed in the medial head of the gastrocnemius muscle. Anesthesia was achieved with subcutaneous lidocaine. Subcutaneous tissue was dissected, and ≈250 mg of muscle was removed and immediately prepared for freezing at -80°C. At 6-month follow-up, the biopsy was repeated, adjacent to the original biopsy, identifiable by the scar.</description>
          <population>Ten and 6 study participants in the cocoa and placebo groups, respectively, completed muscle biopsy at baseline and 6-month follow-up.</population>
          <units>Arbitrary units</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abundance of PGC1α</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="-0.09" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-0.21" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abundance of myostatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="0.05" upper_limit="0.47"/>
                    <measurement group_id="O2" value="0.15" lower_limit="-0.14" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abundance of follistatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.20" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.09" lower_limit="-0.15" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline MRI-Measured Calf Skeletal Muscle Perfusion</title>
        <description>Arterial spin labeling with cardiovascular magnetic resonance imaging was used to measure changes in calf perfusion at 3 T between PAD participants receiving cocoa versus placebo. A thigh cuff was inflated to 250 mm Hg in the leg with the lowest ABI and rapidly deflated after 5 minutes. Seven control-tagged image pairs were acquired over 60 seconds using pulsed arterial spin labeling pulse sequence with single-shot echo-planar imaging readouts ( eld of view, 200×200 mm; matrix, 64×64; repetition time, 4000 ms; echo time, 32 ms; slice thickness, 10 mm). Perfusion was measured and quantified on a Siemens Healthcare workstation by coinvestigator C.M.K.</description>
        <time_frame>Change from baseline to six-month follow-up</time_frame>
        <population>Thirteen and 13 study participants in the cocoa and placebo groups, respectively, completed MRI testing at baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Cocoa</title>
            <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline MRI-Measured Calf Skeletal Muscle Perfusion</title>
          <description>Arterial spin labeling with cardiovascular magnetic resonance imaging was used to measure changes in calf perfusion at 3 T between PAD participants receiving cocoa versus placebo. A thigh cuff was inflated to 250 mm Hg in the leg with the lowest ABI and rapidly deflated after 5 minutes. Seven control-tagged image pairs were acquired over 60 seconds using pulsed arterial spin labeling pulse sequence with single-shot echo-planar imaging readouts ( eld of view, 200×200 mm; matrix, 64×64; repetition time, 4000 ms; echo time, 32 ms; slice thickness, 10 mm). Perfusion was measured and quantified on a Siemens Healthcare workstation by coinvestigator C.M.K.</description>
          <population>Thirteen and 13 study participants in the cocoa and placebo groups, respectively, completed MRI testing at baseline and 6-month follow-up.</population>
          <units>ml/min/100 gram</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-0.25" upper_limit="0.45"/>
                    <measurement group_id="O2" value="-0.32" lower_limit="-0.67" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline Calf Skeletal Muscle Measures: Citrate Synthase and COX Activity</title>
        <description>An open-muscle biopsy at baseline was performed in the medial head of the gastrocnemius muscle. Anesthesia was achieved with subcutaneous lidocaine. Subcutaneous tissue was dissected, and ≈250 mg of muscle was removed and immediately prepared for freezing at -80°C. At 6-month follow-up, the biopsy was repeated, adjacent to the original biopsy, identifiable by the scar.</description>
        <time_frame>Change from baseline to six-month follow-up</time_frame>
        <population>Ten and 6 study participants in the cocoa and placebo groups, respectively, completed muscle biopsy at baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Cocoa</title>
            <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Calf Skeletal Muscle Measures: Citrate Synthase and COX Activity</title>
          <description>An open-muscle biopsy at baseline was performed in the medial head of the gastrocnemius muscle. Anesthesia was achieved with subcutaneous lidocaine. Subcutaneous tissue was dissected, and ≈250 mg of muscle was removed and immediately prepared for freezing at -80°C. At 6-month follow-up, the biopsy was repeated, adjacent to the original biopsy, identifiable by the scar.</description>
          <population>Ten and 6 study participants in the cocoa and placebo groups, respectively, completed muscle biopsy at baseline and 6-month follow-up.</population>
          <units>(nmol/min/mg protein)</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Citrate synthase activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-3.85" upper_limit="3.36"/>
                    <measurement group_id="O2" value="-1.10" lower_limit="-5.98" upper_limit="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COX activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" lower_limit="-37.2" upper_limit="28"/>
                    <measurement group_id="O2" value="-90" lower_limit="-134.1" upper_limit="-46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were formally asked once per month (1 mo, 2 mo, 3 mo, 4 mo, 5 mo, 6 mo) whether or not they had any hospitalizations.</time_frame>
      <desc>The following categories were used to define serious adverse events-&#xD;
Death&#xD;
Cardiovascular events associated with hospitalization&#xD;
Hospitalizations for operations or medical conditions other than cardiovascular events.&#xD;
An untoward medical occurrence resulting in persistent or significant disability/incapacity.&#xD;
Excessive weight gain in the amount of 20 pounds or more.&#xD;
Information regarding other adverse events was not collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cocoa</title>
          <description>Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.&#xD;
Cocoa</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Three servings per day of placebo beverages for six months.&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Hospitalization for shortness of breath and subsequent heart attack and death.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic enlargement with associated symptoms</sub_title>
                <description>Hospitalization for symptoms from an enlarged prostate</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Hospitalized for difficulty breathing and swollen ankles, possibly caused by atrial fibrillation or centrilobular emphysema.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Hospitalization for coughing and pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Food ulcer with cellulitis</sub_title>
                <description>Hospitalization for infection on his foot. Participant received IV antibiotics and was discharged to a nursing home for subsequent IV antibiotic therapy.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lower extremity revascularization</sub_title>
                <description>Hospitalization for right lower extremity bypass surgery.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Other/unknown</sub_title>
                <description>Hospitalization for acute occlusion of the right femoral artery. She underwent thrombectomy and thrombolysis.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <description>Hospitalization for ischemic stroke.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary McDermott, MD, Jeremiah Stamler Professor</name_or_title>
      <organization>Northwestern University</organization>
      <phone>1 312 503 6419 ext 6419</phone>
      <email>mdm608@northwester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

